PRME Insider Trading
Insider Ownership Percentage: 23.47%
Insider Buying (Last 12 Months): $20,000,000.00
Insider Selling (Last 12 Months): $0.00
Prime Medicine Insider Trading History Chart
This chart shows the insider buying and selling history at Prime Medicine by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Prime Medicine Share Price & Price History
Current Price: $2.91
Price Change: ▲ Price Increase of +0.02 (0.69%)
As of 01/21/2025 05:00 PM ET
Prime Medicine Insider Trading History
Prime Medicine Institutional Trading History
Data available starting January 2016
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
Read More on Prime Medicine
Volume
767,027 shs
Average Volume
813,190 shs
Market Capitalization
$381.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.86
Who are the company insiders with the largest holdings of Prime Medicine?
Who are the major institutional investors of Prime Medicine?
Which major investors are buying Prime Medicine stock?
Within the last quarter, PRME stock was purchased by institutional investors including:
- Green Alpha Advisors LLC
- Avanza Fonder AB
- Impact Partnership Wealth LLC
- SG Americas Securities LLC
- Nisa Investment Advisors LLC